Minerva Neurosciences, Inc. (NERV) Stock

Minerva Neurosciences, Inc. (NERV) is a Healthcare stock trading at $4.82 (as of 2026-08-21), with a market capitalization of $230.14M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company developing and commercializing product candidates for central nervous system diseases. Its main candidates include roluperidone for schizophrenia and MIN-301 for Parkinson’s disease and other neurodegenerative disorders, with a license agreement with Mitsubishi Tanabe Pharma for development, sales, and import of roluperidone globally excluding Asia.

Understand Minerva Neurosciences, Inc.: how it makes money

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing CNS disease treatments, including roluperidone for schizophrenia and MIN-301 for Parkinson's disease, and it aims to commercialize them (with roluperidone licensed from Mitsubishi Tanabe Pharma Corporation, globally excluding Asia).

The companys profit potential is structurally tied to whether its CNS product candidates (especially roluperidone under its Mitsubishi Tanabe license with geographic exclusions) progress successfully through clinical development and can be commercialized.

Business quality (Mixed): Clear focus on two CNS product candidates and a defined roluperidone licensing arrangement, but there is not enough official segment detail here to connect operating performance to specific revenue streams.

Bull case

Two CNS programs with defined leads: The company focuses on roluperidone for schizophrenia and MIN-301 for Parkinson's disease and other neurodegenerative disorders.
Trackable development progress: Disclosed trial enrollment metrics include 513 patients entering double-blind phase and 333 patients entering open-label extension.
Rolupreridone has an established commercial licensing framework: Minerva has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia.

Bear case

Clinical outcomes are uncertain: Key trial metrics include an overall relapse rate of 11.7% and open-label relapse rate of 12.0%, which may reflect ongoing efficacy or tolerability challenges.
Program timelines and patient retention can change: Patients completed nine-month open label extension are listed as 202, which implies drop-off from initial entry into the open-label extension.
Geographic limits on roluperidone rights: The Mitsubishi Tanabe license for roluperidone covers development, sale, and import globally excluding Asia, which can constrain addressable commercial reach.

Valuation — source: SEC EDGAR (first-party)
Price	$4.82
Market Cap	$230.14M
Price / Sales	118.91

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$948122.00
Net Margin	-30947.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	-8.83 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.0

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	FEDERATED HERMES, INC. ($30.81M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Remy Luthringer
Employees	8
Country	US
IPO Date	2014-07-01

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.